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The urokinase-type plasminogen activator (UPA) is considered to play a key role in the process of 
invasion and metastasis. In several independent studies, in a variety of cancer types (e.g. of the breast, 
colon, stomach, lung, ovary), high antigen levels of UPA in tumour extracts have been associated with 
rapid disease progression. In these studies, different sets of antibodies and standards (often as 
commercially available uFA ELISA kits) have been used. The standards provided with the different 
UPA ELISA kits are different from each other in both composition and source. In addition, the different 
UPA ELISA kits use antibodies which differ in specificity and afBnity for the various forms of UPA 
including pro-UPA, HMW-uI?A, LMW-UPA, the aminoterminal fragment (ATF) and complexes with 
inhibitors (FAI-1 and PAI-2) and the receptor @FAR). Further, the composition of tumour tissue 
extraction buffers differ significantly among the published studies. Thus, it is not surprising that the 
ranges of cytosolic ul?A levels reported differ considerably even when measured within the same tumour 
type. These discrepancies led the EORTC Receptor and Biomarker Study Group, in conjunction with 
the BIOMED-1 consortium on ‘Clinical Relevance of Proteases in Tumour Invasion and Metastasis’, 
to organise a workshop to study the characteristics associated with six different UPA immunoassays 
(ELISA) used in clinical studies reported in the literature. Although the absolute UPA antigen values 
measured with the respective UPA ELISA kits differed, high correlations were obtained for any two of 
the four UPA ELISA kits finally applied to sets of breast cancer cytosol preparations. The preparations 
used at present as standards in the various UPA ELISA kits are not representative of actual human 
breast cancer cytosols. Thus absolute standardisation is only possible by using a common reference 
sample (breast cancer cytosol) and similarly composed ELISA uPA kits. Then it will be possible to 
generate comparable data on clinical tissue as well as to check for batch-to-batch variations within 
particular ELISA kits. Copyright 0 1996 Elsevier Science Ltd 
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INTRODUCTION disease. Lymph node status is recognised as one of the best 
IN BREAST cancer, the selection of high-risk patients has always clinical discriminants between good and bad prognosis. Yet 
been difficult due to the unpredictable biological course of the almost 30% in node-negative patients will relapse within a few 
months, while in node-positive patients approximately 25% 
are free of disease 10 years after primary surgery [ 11. 
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tissue. Early work showed that oestrogen receptor positivity 
was associated with longer survival [24], most probably 
because oestrogen receptor-positive patients are the ones most 
likely to respond to steroid hormone therapy. Quantification 
of oestrogen receptor is important because the chance of 
patients responding to hormonal therapy is proportional to 
the oestrogen receptor content in the primary tumour [5-71. 
For this reason, determination of biological indices should be 
quantitative, rather than qualitative. In consequence, quality 
assurance groups have been established to monitor tumour 
biology factors, e.g. steroid hormone receptors [8-lo]. 
To increase the knowledge of the biological basis of tumour 
development, various studies have been undertaken to look 
into the mechanism of tumour invasion. A major component 
of tumour invasion is the action of tumour-associated pro- 
teases in disrupting the surrounding basement membrane and 
the adjacent stromal matrix. The action of these proteases is 
under control of a cascade response which induces activation 
of proteolytically active urokinase (UPA) from its precursor 
pro-uPA [ 1 l-131. Recent studies have suggested that the uPA 
level might be a strong biological indicator of prognosis in 
breast cancer [14,15] and of response to endocrine therapy in 
recurrent breast cancer [16]. There is also broad interest in 
the relationship of uPA levels with other types of cancer [ 17- 
19]. Various ELISAs for UPA have been established and 
reported in the literature, and some of these are commercially 
available. 
During a workshop held in Nijmegen, The Netherlands, 
under the auspices of the EORTC and the BIOMED-1 pro- 
gramme supported by the European Community, a number 
of UPA ELISAs were tested. The present report contains 
results of uPA measurements obtained during this workshop 
supplemented with data collected in later studies. Attention 
was paid to the immunological potencies of various standards, 
to parallelism, to detection limits and to within- and between- 
assay variations achievable. 
It should be kept in mind that the purpose of this study was 
not to evaluate the quality of the individual methods, but to 
better understand the characteristics associated with each of 
the procedures. 
PATIENTS AND METHODS 
orgunimion 
Within the framework of both the Receptor and Biomarker 
Study Group of the EORTC and a consortium of the 
BIOMED-1 programme ‘Clinical Relevance of Proteases in 
Tumour Invasion and Metastasis’, a workshop was organised 
in Nijmegen. A number of different ELISA kits were used to 
assess UPA antigen in primary breast cancer. The companies 
that generously made their reagents available are American 
Diagnostica (Greenwich, U.S.A.), Biopool (Umea, Sweden), 
Oncogene Science (Cambridge, U.S.A.), Sangtec Medical 
(Bromma, Sweden) and Technoclone (Vienna, Austria). In 
addition, the group was provided with the relevant reagents to 
determine uPA by the Finsen Institute (Copenhagen, 
Denmark), a laboratory with a longstanding experience in the 
uPA field. Comparable reagents are commercially available 
from Monozyme (Denmark). Many, but not all, participants 
had previous experience with these assays. It is reasonable to 
assume that the experience of the operators will have positively 
influenced the performance of the assays during the workshop. 
At the workshop, measurements of PAI- 1, a natural occurring 
inhibitor, and the receptor uPAR, were also investigated and 
will be the subject of future publications. 
Samples 
Primary breast cancer biopsies from our tumour bank 
(- 80°C) were analysed. Xenografts, raised in nude mice after 
implanting MDA-NB-231 human breast cancer cells, were 
kindly provided by the Finsen Institute. Biopsies and xeno- 
grafts were homogenised (microdismembrator) in EORTC 
buffer (20 mM KaHPO,/KH,PO,, 1.5 mM KaEDTA, 3 mM 
sodium azide, 10 mM monothioglycerol, 10% [v/v] 
glycerol/water, pH 7.4), centrifuged at 8OOg, the supernatant 
collected and subjected to cennifugation for 1 h at 1OOOOOg 
at 4°C. This procedure has for many years been used to 
make cytosols for measuring the oestradiol and progesterone 
receptor levels. It is worthwhile mentioning that this pro- 
cedure was used to collect cytosolic proteins. However, UPA 
in addition to its free state is also bound to its receptor, uPAR. 
Therefore, in various published studies, detergent-containing 
buffers have been used for extraction of UPA. However, it has 
been the experience of various laboratories that while the uPA 
content of these extracts are much higher than the values 
obtained in the EORTC cytosol, there is a close correlation 
between the values obtained with the two techniques [20] (see 
also the Results section). Dilution of cytosols was performed 
applying dilution buffers recommended for that particular 
assay procedure. The following extraction buffers were used 
for pellet extraction: (1) Jiinicke buffer: 20 mM Tris-HCl, 
125mM NaCl containing 1% Triton X-100, pH8.5 [2OJ; 
and (2) Camiolo buffer: 75 mM potassium acetate, 0.3 M 
NaCl, 0.1 M L-arginine, 10 mM KaEDTA, 0.25% Triton X- 
100, pH 4.2 [21]. 
Standards 
The NIBSC UPA standard 87J594, consisting of highly 
purified HMW uPA derived from human urine, was kindly 
provided by Dr P.J. Gaffiey (NIBSC, U.K.). Until now, this 
standard has not officially been assigned an antigen value. For 
internal purposes, NIBSC use the value of 32.5 &ampoule. 
This standard for high molecular weight urokinase (HMW- 
UPA) is alternatively named HMW-two chain UPA (HMW- 
tc-uPA) . 
The UPA standard provided with the American Diagnostica 
ELISA kit, designated as SC-UPA, is a glycosylated pro-uPA, 
secreted by a cell line and purified from conditioned culture 
media. The Grtinenthal standard (Saruplase@) is a recombi- 
nant non-glycosylated pro-urokinase produced by E. coli, gen- 
erously provided by Griinenthal GmbH, Stolberg, Germany. 
The pro-uPA content has been determined by Gtinenthal on 
the basis of amino acid determination. The Finsen laboratory, 
in their published studies, used the NIBSC standard as well 
as the Grtinenthal preparation, calibrated against the former 
WI. 
Analytical methods 
The basic characteristics of the different ELISAs are shown 
in Table 1, including the type and range of standards used, 
the type of primary and secondary antibodies employed and 
information about the forms of UPA recognised by the relevant 
assay system. This information was provided by the manufac- 
turers. 
The ELISAs were all of the sandwich type. The ELISAs 
were all performed in precoated microtitre plates using spec- 
Report of a Workshop on UPA Immunoassays 1373 
Table 1. Characteristics of uPA ELISXs 
Company/institute 
(trade name) 
Type of standard and 
antibodies (ftom 
inserts) 
Forms of uPA 
recognised (from 
inserts) 
American Diagnostica: SC-uPA standard SC-uPA, HMW 
(Imubind” uPA) range: O-l @ml, uPA, UPA-uPAR, 
primary antibody: UPA-PAI- 1, UPA- 
monoclonal, PAI-2 
secondary antibody: 
monoclonal-biotin, 
streptavidin-HRP- 
TMtB: 450 nm 
Finsen: NIBSC standard, SC-uPA, HMW 
Reagents for UPA HNLW UPA 87/594, UPA, uPA-inhibitor, 
assay range: O-1 &ml, UPA-uPAR, LMW 
primary antibody: UP A 
polyclonal, secondary 
antibody: 3 
monoclonals-biotin, 
streptavidin-HRP- 
OPD: 490/620 nm 
Biopool: pro-uPA standard, SC-uPA, HMW 
(TintElize” UPA) range: O-4 @ml, uPA, L.MW UPA 
primary antibody: 
monoclonal, 
secondary antibody: 
polyclonal-HRP, 
OPD: 490 nm 
Sangtec: HMW UPA standard, SC-uPA, HMW 
UPA LIA range: O-40 @ml, UPA, UPA-uPAR, 
primary antibody: UPA-PAI- 1 
monoclonal, 
secondary antibody: 
monoclonal-lumin, 
luminometer 
Technoclone: uPA. standard, range: SC-UPA, tc uPA, 
TC” uPA Ckl 0 rig/ml, primary uPA-sexpin, 
antibody: complexes 
monoclonal, 
secondary antibody: 
HRP-antibody, 
ABTS: 405 run 
Oncogene Science: pro-uPA standard, SC-uPA, HMW 
uPA Elisa range: O-350 pg/ml, uPA, LMW uPA, 
primary antibody: 2 UPA-uPA& UPA- 
mon.oclonals, PAL1 
secondary antibody: 
polyclonal, final 
antibody: HBP- 
antibody, OPD: 
4901620 run 
HRP, horseradish peroxidase; TMB, tetramethyl be&dine; OPD, 
ortho-phenylenediane; ABTS, azido-bis thiazoliue-sulphonic acid. 
trophotometric determinations, whereas the LIA type of 
ELISA, using a luminometric detection system was performed 
in antibody precoated tubes. The ELISAs were used accord- 
ing to the instructions provided by the manufacturers. The 
ELISA developed in the Finsen laboratory was used as pre- 
viously described [ 181. No major difficulties were noticed 
while performing the assqys. 
The lower limit of detection was defined as three standard 
deviations in the measurement of zero analyte. The overall 
coefficient of variation (CV) was calculated using the formula 
overall CV% = square root of Z [CV%JZIn). 
RESULTS 
Standard cupues in different assay procedures 
Figure 1 shows representative standard curves obtained 
using six different UPA procedures and the standards provided 
by the companies with their different kits. All curves were 
more or less curvilinear. The Finsen and American Diagnos- 
tica procedures (Figure 1 a, b) employ a working range from 0 
to 1 ng/ml. The lower limits of detection were nearly identical. 
The overall CVs of the standard points were 8.1 and 7.5%, 
respectively. These characteristics are in agreement with the 
information given in the kit-insert. 
The standard curve obtained using the Sangtec kit (Figure 
lc) shows the relationship between relative light units (RLUs) 
and the amount of UPA, up to 4 r&ml. The lower detection 
limit was calculated to be as low as 0.010 &ml (1.0 pg per 
tube), with an overall CV of 4.4%. The span of the standard 
curve in the Oncogene Science procedure (Figure Id) ranged 
from 0 to 0.35 ng/ml. In this very sensitive assay, the detection 
limit was 0.002 r&ml. In contrast to the aforementioned 
assays, the Biopool uPA assay (Figure le) was specifically 
designed for the quantitative determination of uPA in plasma 
samples. For this purpose, the detection limit of 0.277 ng/ml 
is adequate. The Technoclone assay (Figure lr> is also 
specifically intended for the determination of uPA in plasma, 
and the highest standard used is 10 r&ml. The lower limit of 
detection was calculated at 0.384 &ml, with an overall CV 
of 4.9%. 
In the four most sensitive assays (Finsen, American Diag- 
nostica, Sangtec, Oncogene Science) five different types of 
standards were tested. Figure 2 shows that the slopes of the 
curves in all methods varied considerably. Obviously, in all 
assay methods, the values measured in unknowns depend 
strongly on the standard applied. It is worth noting that the 
immunoreactive potencies, as reflected by the absorbance 
values, of the different standards do not follow the same order 
in the different assay procedures. For instance, in three out of 
the four procedures (Finsen, Sangtec, Oncogene Science) the 
HMW-uPA standard provided with the Sangtec kit, gave the 
highest signal, whereas the lowest signal was evoked by the 
Biopool pro-uPA standard. In contrast, in the American Diag- 
nostica procedure little difference in optical density was 
observed using these two standards. 
Correlation and comparison between cytosohc t&A assay methods 
Figure 3a shows uPA values measured in 117 breast cancer 
cytosols both with the American Diagnostica procedure and 
the Finsen assay method (both methods used in previous 
publications). The values obtained by the American Diagnos- 
tica kit ranged from 0 to 8.14 ng/ml; the values obtained by 
the Finsen procedure ranged t?om 0.16 to 9.05 r&ml. In the 
Finsen procedure the pro-uPA from Griinenthal was used as 
a standard and in the American Diagnostica assay the sc- 
uPA standard provided with the kit. Least squares regression 
analysis of the data gave the relationship y = 1.13x + 0.17. 
Although the strength of relation is very high (r = 0.950), this 
is not an appropriate indicator of agreement between the 
methods. For an adequate assessment of how closely the two 
methods agree, a so-called Difference Plot [23] was produced 
(Figure 4a). This figure reveals the true extent of the bias 
especially at low UPA concentrations. In 5 of the 117 samples, 
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(a) Finsen 
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2.Or 
mean CV 7.5% 
low.det.limit 0.032 ng/ml 
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0 0.2 0.4 0.6 0.8 1.0 
uPA @g/ml) 
(d) Oncogene Science 
2.5r 
mean CV 6.3% 
low.det.limit 0.002 nglml 
0 0.05 0.10 0.15 0.20 0.25 0.30 0.35 
uPA (ng/ml) 
(f) Technoclone 
1.6- 
mean CV 4.9% 
low.det.limit 0.384 ng/ml 
I I I I I 
2 4 6 8 10 
uPA (ng/ml) 
Figure 1. Representative standard curves for six different uPA assays. Measurements were performed in duplicate (low. det. 
limit, lower limit of detection). 
the uPA values measured with the American Diagnostica were used. The values obtained by the American Diagnostica 
procedure were lower than the detection limit, whereas in the procedure ranged between 0.82 and 8.58 &ml; in the Sang- 
Finsen procedure the values were low but measurable. These tee procedure the values were between 0.06 and 4.57 ng/ml. 
five samples were excluded from the Difference Plot. Of the These values were highly correlated (Figure 3b). The relation 
American Diagnostica values 87 were lower, 1 was equal and between the Sangtec values and the American Diagnostica 
29 were higher than in Finsen procedure. values is defined by y = 0.60x - 0.36. The respective Differ- 
Breast cancer cytosols (n = 18) were also analysed with ence Plot is shown in Figure 4b. Although the number of 
both the Sangtec procedure and the American Diagnostica observations is rather small, there is a tendency for a decrease 
kit. In both assays the standards provided by the companies in percentage difference at higher uPA concentrations. 
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(a) Finsen 
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(b) American Diagnostica 
2.4r 
(C) Sangtec 
60000 
r 
uPA (ng/ml) uPA (nglml) 
uPA @g/ml) 
(d)Oncogene Science 
3.0r 
Figure 2. Standard curves constructed by using various uPA standard preparations (Sangtee (O), pro-uPA Grhenthal (A), sc- 
UPA American Diagnostica (0), NIBSC 871594 (+), Biopool (A) and Oncogene Science (O)), and employing four different UPA 
assays. 
A number of other breast cancer cytosols (n = 34) were 
analysed with both the Chicogene Science and the American 
Diagnostica kit. In this series the span of uPA values obtained 
with the latter ranged between 0.08 and 4.97 ng/ml and the 
Oncogene Science values ranged between 0.21 and 
10.6ng/ml. Figure 3c shiows the linear relation with a high 
correlation coefficient. The relation between UPA values 
obtained with the Oncogene Science and the American Diag- 
nostica kit is defined by y = 2.10x + 0.38. The Difference 
Plot is shown in Figure 4c, implying that over the whole range 
of UPA concentrations the difference between the results 
obtained with both procedures is remarkably constant. 
The repeatability of the three assay procedures is reflected 
by the CVs shown in Tablle 2. The UPA values measured were, 
for each procedure, divided into four quartiles. The CVs 
calculated from duplicates were averaged and are shown in 
the last column of the table. All coefficients of variation 
calculated were acceptable. The CV calculated from the 18 
duplicate Sangtec measurements was 14.6%. The kits from 
Biopool and Technoclone, designed for UPA measurement in 
plasma, were not included in these experiments because they 
would require undiluted cytosol samples. 
Dilution of cytosolic samples 
The different assay procedures recommend that samples be 
diluted to within a specified range of protein content prior to 
assay. Values corrected for dilution should give the same result 
irrespective of the extent of dilution. Dilution experiments 
were carried out using both the Finsen assay and the American 
Diagnostica procedure. Such experiments are often referred 
to as parallelism studies because dilutions of sample should 
parallel the standard curve. In Table 3 the results obtained 
with the Finsen procedure are displayed. A human breast 
cancer cytosol (no. l), prepared according to the EORTC 
guideline, was diluted with the appropriate dilution buffer 
obtaining dilutions from l/4 to l/64. The actual UPA concen- 
trations measured in the diluted samples ranged from 0.067 
to 0.866 @ml. The corresponding CVs calculated from the 
duplicates ranged from 0.9 to 6.3%. Multiplying these con- 
centrations by the appropriate dilution factor will give the 
actual UPA value in the undiluted sample. The mean of these 
UPA values was 3.7 rig/ml and the CV was calculated to be 
9.4%. Evidently, no systematic error could be detected, i.e. a 
perfect parallelism was observed. Three different ‘xenograft 
cytosols’ (nos 2, 3 and 4) with high UPA concentrations were 
diluted even further, obtaining dilutions down to 11400. The 
CVs observed analysing UPA in the dilutions were <5%. 
Again, no systematic error was observed and parallelism was 
ascertained. In another set of dilution experiments performed 
with the American Diagnostica procedure, comparable results 
were obtained (see Table 4). No systematic decrease or 
increase of uPA levels was seen upon dilution. 
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(a) Finsen (b) Sangtec 
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American Diagnostica (ng/ml) American Diagnostica (ng/ml) 
(C) Oncogene Science 
12 r 
American Diagnostica (ng/ml) 
Figure 3. Correlation of uPA levels in human primary breast tumour cytosols assayed with the American Diagnostica kit and 
the Fmsen procedure (a), Sangtec kit (b) and the Oncogene Science kit (c). 
&A in tissue p llet extracts 
In the experiments described so far, UPA was assessed in 
cytosolic extracts employing the routine EORTC buffer as 
originally described for determination of steroid hormone 
receptors. However, UPA was also measured in tumour pellet 
extracts. Ten mammary tumours were homogenised in the 
EORTC buffer and the homogenates were pooled and divided 
into two equal parts. After centrifugation at IOOOOOg the 
cytosol was separated from the pellets. One pellet was 
extracted with a buffer previously described by J%nicke and 
colleagues [20] which contains the non-ionic detergent Triton 
X-100 (pH 8.5). The other pellet was extracted with a buffer 
described by Camiolo and coworkers [21]. This latter buffer 
has a high ionic strength and a low pH (pH 4.2). Both extracts 
were diluted to various extents not with the extraction buffers 
but with the appropriate dilution buffers belonging to the 
particular assay procedure. uPA was measured with six differ- 
ent assay procedures. 
The various dilutions in which uPA was assayed are shown 
in Table 5. The table shows that for the various assay pro- 
cedures the dilutions varied, taking into account the different 
sensitivities of the asssay procedures. With each assay pro- 
cedure, five different dilutions of both the Camiolo and Jan- 
icke extracts were analysed and each was measured five times. 
The results are presented in Table 6. It is noteworthy that the 
uPA values in the JsLnicke extracts were lower than the levels 
present in the Camiolo extracts. This holds for all six assay 
procedures. Obviously, because of the use of different internal 
standards and different antibodies, a large variation was 
observed between the uPA values obtained employing the 
different assay procedures. 
The degree of parallelism, which can be deduced from the 
uPA values measured in the different dilutions, was higher 
when the pellet extraction was performed with the J&nicke 
buffer. This holds for three of the assay procedures (Finsen, 
American Diagnostica and Sangtec). The strongest parallel- 
ism was observed using the Oncogene Science kit. In those 
assay procedures which were developed for uPA analysis in 
plasma samples, less diluted tumour extracts could be used. 
In those cases, matrix effects resulted in non-parallelism. 
UPA values in cytosolfiactions versus corresponding pellet extracts 
Nine primary breast cancers were homogenised in EORTC 
bufler and uPA was measured in the cytosols. The 1OOOOOg 
pellets were extracted with the Camiolo buffer and uPA was 
measured in these extracts (Figure 5). There was a strong 
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(a)American Diagnostica (A) versus Finsen (F) (b) American Diagnostica (A) versus Sangtec (S) 
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Figure 4. Difference plots of measured UPA levels in breast tumour cytosols with the American Diagnostica kit (A) compared 
with (a) the Finsen procedure (F); (b) the Sangtec kit (S) and (c) the Oncogene Science kit (0). The percentage difference 
between two assays is plotted as the thction of the level of uPA [22]. 
American Diagnostica 160 21 
0.16-0.38 ng/ml 11.7 
0.39-0.60 nghnl 12.0 
0.62-1.10 nghnl 10.2 
1.1 l-3.45 @ml 7.6 
Finsen 130 0 
0.24-0.90 q/ml 9.0 
0.94-1.64 r&ml 9.4 
1.68-2.92 &ml 3.2 
3.02-9.00 &ml 2.7 
Oncogene Science 34 0 
0.21-1.48 &ml 4.0 
1.86-3.17 ng/ml 2.9 
3.73-5.68 ng/ml 5.6 
5.70-10.64 &ml 3.3 
Table 2. Coejjcients of variation based on duplicate measurements 
obtained at various UPA concentration ranges 
uPA ranges 
Number of Number under Average CVs 
duplicates detection limit (%I 
correlation between the soluble and detergent-extracted 
values. The Camiolo extracts contained 50 times higher UPA 
concentrations compared1 with the values in the corresponding 
cytosols. The UPA values presented in the figure are expressed 
per mg protein present in the samples. When the UPA concen- 
trations were expressed per ml of sample, the Camiolo extracts 
contained 10 times higher UPA values than the corresponding 
cytosols 0, = 10.48x - 5.57, r = 0.924). 
Analysis of a lyophilised quality control sample 
To be able to perform a.dequate internal and external quality 
control on the assays, a representative and stable control 
sample is needed. Therefore, cytosols prepared from primary 
breast cancer tissues were pooled and the pool was spiked 
with recombinant pro-uPA and lyophilised. This control sam- 
ple was analysed on 26 separate days divided over a period of 
18 months (Figure 6). Three operators performed the assays 
using various batches of the UPA kit from American Diagnos- 
tica. The mean of 26 uPA concentrations was 10.9 r&ml with 
an overall CV of 11.5%. No statistically significant trend 
was observed. 
DISCUSSION 
The proteolytic enzyme UPA, which activates plasminogen 
to the protease plasmin, plays an important role in cancer 
invasion and metastasis. In a preliminary report, in. 1988, 
evidence was presented that high UPA enzyme activity in 
breast carcinoma extracts correlated with a shortened disease- 
free interval for the patients [ 141. Two years later, in 1990, 
two groups of investigators, Jlnicke and coworkers and D&l+ 
and coworkers independently reported measurements of ul?A 
antigen content in breast cancer tissues [15, 241. Applying 
completely different UPA ELISAs, these authors reported that 
a high level of immunoreactive uPA is significantly correlated 
with high relapse rate and associated with poor prognosis. 
These observations were later extended and confirmed in 
other studies [25-271. The uPA ELISA kits employed differed 
in the type of antibodies used, in the type of standards and in 
the instructions on how the tissue extracts had to be prepared. 
Notwithstanding these differences in analytical features, caus- 
ing different ranges of values and cut-off points, the same 
clinical relevance for UPA was observed in all these studies. 
The different sandwich-type uPA ELISAs used in those 
particular studies were included in the experiments of the 
present study, along with reagent kits marketed more recently 
or designed for UPA measurement in plasma. It was found 
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2t 
3t 
1* 4 0.866 0.9 3.5 
8 0.458 2.1 3.7 mean 3.7 ngiml 
16 0.213 3.7 3.4 SD 0.35 nglml 
32 0.116 5.7 3.7 cv 9.4% 
64 0.067 6.3 4.3 
100 0.704 1.6 70.4 
150 0.473 4.1 71.0 
200 0.354 3.2 70.8 mean 71.1 ng/ml 
300 0.225 6.4 67.5 SD 2.91 &ml 
400 0.189 6.1 75.6 cv 4.0% 
100 0.928 2.1 92.8 
150 0.614 3.1 92.1 
200 0.455 1.1 91.0 mean 92.6 &ml 
300 0.312 2.4 93.6 SD 1.10 ngml 
400 0.234 3.6 93.6 cv 1.2% 
100 0.956 3.0 95.6 
150 0.696 4.2 104.4 
200 0.538 0.1 107.6 mean 101.2 &ml 
300 0.328 0.1 98.4 SD 4.79 &ml 
400 0.250 0.2 100.0 cv 4.7% 
4t 
Table 3. Parallelism study by dilution of cywsolic samples (Finsen procedure) 
Cytosol 
nr Dilution factor 
uPA (ngml) 
measured in diluted sample; 
mean of duplicates 
% CV from 
duplicates 
uPA (q/ml) 
calculated in 
undiluted sample 
*Mammary tumour cytosol. tThe cytosols were prepared from three different xenografts raised in nude mice after applying MDA-NB-23 1 
human breast cancer cells. 
Table 4. Parallelism study by dilution of cytosolic samples (American Diagnostica) 
Cytosol 
nr Dilution factor 
uPA (ng/ml) measured in 
diluted sample; 
mean of duplicates 
% CV from 
duplicates 
uPA (&ml) 
calculated in 
undiluted sample 
5* 20 0.119 5.1 2.4 
50 0.050 8.8 2.5 mean 2.6 @ml 
100 0.030 5.0 3.0 SD 0.26 &ml 
200 0.013 5.5 2.6 cv 10.0% 
6* 50 0.132 1.0 6.6 
100 0.068 18.5 6.8 mean 7.0 &ml 
200 0.039 10.4 7.8 SD 0.54 &ml 
400 0.017 2.9 6.8 cv 7.7% 
7t 50 0.612 5.0 30.6 
100 0.328 1.2 32.8 mean 30.9 ng/ml 
200 0.139 6.6 27.8 SD 2.28 &ml 
400 0.081 0.0 32.4 cv 7.4% 
8$ 10 1.023 4.7 10.2 
20 0.572 11.4 11.4 mean 10.5 &ml 
40 0.289 9.1 11.6 SD 0.97 ngml 
80 0.120 5.4 9.6 cv 9.2% 
120 0.080 7.1 9.6 
*Mammary tumour cytosol. tColon carcinoma cytosol. SMammaty tumour cytosol spiked with 8.4 ng/ml pro-uPA. 
that those kits developed for the analysis of tumour cytosols, When, during our workshop, sets of breast cancer cytosol 
all reached sensitivities of less than 32 pg uPA per ml, which preparations were analysed applying different UPA ELISAs, 
is satisfactory. The two UPA ELISAs, initially developed for different absolute uPA values were observed, although high 
measuring UPA in plasma, did not reach the desired sensi- correlations (Pearson) were obtained for any two of the four 
tivity, but recently these assays have been redesigned and are UPA ELISAs applied. It is acknowledged that, strictly speak- 
now available for tumour extract analysis. The within-assay ing, the Pearson correlation coefficient is a poor index of the 
CVs observed, employing the various assay methods, were degree of agreement between two methods [23]. How closely 
acceptable, and all kits designed for tumour analysis displayed two methods agree is a question which is more accurately 
an acceptable to excellent degree of parallelism. answered by employing a calculation of the differences 
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Table 5. Dilutions of the pellet extracts analysed 
Pellet extracted 
with Jiinicke buffer* 
> 
>> 
>>> 
>>>> 
>>>>> 
Camiolo buffer* 
> 
>> 
>>> 
>>>> 
>>>>> 
American 
Diagnostica 
1:20 
1:40 
1:60 
1:80 
1:120 
1:lO 
1:20 
1:40 
1:60 
1:80 
Sangtec Finsen Biopool Oncogene Science Technoclone 
1:l 1:30 1:lO I:90 1:l 
1:2 1:60 1:20 1:180 1:2 
1:4 1:90 1:30 1:270 1:5 
1:8 1:120 1:40 1:360 1:lO 
1:16 I:150 1:50 1:450 1:20 
1:l 1:20 1:lO 1:60 1:l 
1:2 1:40 1:20 1:120 1:2 
1:4 1:60 1:30 1:180 1:4 
1:8 I:80 1:40 1:240 1:8 
1:16 1:120 1:50 I:360 1:16 
*Extracts were diluted with the appropriate dilution buffer. 
>, lowest dilution; >>>>I>, highest dilution. 
Table 6. UPA values in d@rent dilutions of pelkt extracts* 
Pellet extracted 
with Jiinicke buffer 
> 
>> 
>>> 
>>>> 
>>>>> 
Camiolo buffer 
> 
>> 
>>> 
>>>> 
>>>>> 
American 
Diagnostica 
6. lt (5%)$ 
5.1 (12%) 
4.8 (6%) 
4.5 (7%) 
5.0 (7%) 
13.8 (3%) 
12.9 (2%) 
11.2 (6%) 
lQ.2 (3%) 
9.7 (3%) 
Sangtec Finsen Biopool Oncogene Science Technoclone 
8.2 (5%) 13.7 (4%) OF 17.3 (5%) 11.0 (10%) 
7.5 (2%) 12.9 (5%) OF 17.7 (5%) 15.4 (17%) 
7.7 (3%) 11.3 (4%) 12.2 (86%) 17.7 (15%) 18.3 (7%) 
7.9 (3%) 12.2 (3%) 13.1 (4%) 16.7 (8%) 31.9 (16%) 
9.0 (4%) 12.7 (7%) 14.6 (9%) 16.6 (7%) 37.3 (19%) 
OF 16.3 (12%) OF 23.8 (9%) OF 
12.5 (20%) 16.9 (1%) 43.8 (6%) 24.0 (8%) 21.3 (7%) 
18.3 (21%) 18.9 (4%) 49.2 (11%) 25.6 (14%) 41.2 (14%) 
14.7 (5%) 20.2 (2%) 65.2 (32%) 25.4 (16%) 40.0 (8%) 
15.0 (0%) 22.1 (2%) 49.4 (22%) 24.5 (13%) 42.2 (12%) 
*Values measured five times; tng uPA/ml. *Coefficient of variation. >, lowest dilution; >>>>>, highest dilution; OF, overflow. 
Homogenates of ten mammary tumours were pooled. After centrifugation the pellet was divided into two parts. One part was extracted with 
JSnicke buffer, the other part with Camiolo buffer. 
OW I I 0.6 0.9 
Cytosol; uPA (&ml) 
Figure 5. Comparison of uPA levels measured in breast cancer 
cytosols compared with uPA levels measured in their paired 
Figure 6. Effect of storage on the stability of uPA levels in a 
pellet extracts. Pellets were extracted with the Camiolo buffer, 
lyophilised spiked breast cancer cytosol. Breast cancer cytosol 
and UPA was determined using the Finsen procedure. 
(212 ml) was spiked with 1778 ng recombinant pro-uPA and 
lyophiised in 0.5 ml aliquots. Vii containing the lyophilised 
residue were stored at 4°C. 
n = 26 
mean 10.9 ng/ml 
S.D. 1.3 ng/ml 
cv 11.5% 
I I I I I I I I I 
0 1.6 6.4 6.8 7.3 7.4 8.1 12.3 17.8 
Months of storage 
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between measurements. Scatter plots of the per cent differ- 
ences versus the mean of the two methods provide a clear 
visual indication of the outliers which occur especially at 
low concentrations. 
It is important to note that the uPA values measured with 
the various uPA ELISAs will depend on the efficiency with 
which the different sets of UPA antibodies employed detect 
the various forms of uPA present in the tissue cytosol. Indeed, 
uPA can occur in viva in different molecular forms: as a single 
chain pro-enzyme (pro-uPA); as a high molecular weight two 
chain molecule HMW-UPA; and as a low molecular weight 
LMW-UPA. Besides these different forms, complexes of pro- 
uPA and HMW-uPA with the receptor for uPA,uPAR, are 
present. In addition, HMW-uPA, its receptor-bound form, 
and LMW-uPA can be complexed with the inhibitors PAI- 
or PAI-2, complexes in which uPA-epitopes may be hidden, 
due to steric hindrance. Taken together, this implies that, in 
cytosols, uPA may be present as a mixture of various molecu- 
lar forms and weights with different structures. 
According to Biiessecker and colleagues [28], polyclonal 
antibodies to uPA react with the distinct molecular forms of 
uPA to a similar degree when tested by ELISA. In contrast, 
monoclonal antibodies, due to their high epitope-specific rec- 
ognition, may not a primi allow detection of distinct UPA 
forms and complexes. All the uPA ELISAs tested in the 
present study use monoclonal antibodies, and the information 
given by the manufacturers with the kit claim that most, if not 
all, of the uPA forms are recognised. However, no detailed 
studies regarding this aspect are available and therefore it has 
to be emphasised that the efficiencies with which the various 
forms are detected are reportedly unknown and remain to 
be determined. 
The relative level of each molecular form of uPA present in 
cytosol may vary between different cytosols. The results of the 
present study suggest that this variation will be even greater 
when different ways of extraction are employed, e.g. including 
or excluding non-ionic detergents in the extraction buffer. 
Our results confirm earlier findings [25] which indicated that 
the uPA content in tumour tissue extracts, obtained by treat- 
ing fresh tumour tissues with a Triton X-100 containing 
buffer, is much higher than the uPA level in extracts prepared 
by using the detergent-free EORTC buffer. 
As far as the standards provided with the different kits are 
concerned, these are different in structure (e.g. glycosylated 
versus non-glycosylated) and in source (e.g. recombinant ver- 
sus cell-culture supematants). The results obtained during 
the workshop disclosed large differences in immunological 
potencies of the different standard preparations, when they 
were tested in the various kits. The discrepancies observed 
cannot solely be ascribed to differences in calibration of the 
standards because the immunoreactive potencies, as reflected 
by the different absorbance values generated by different 
standards, do not follow the same order in the different uPA 
ELISAs. For example, when a particular standard in one of 
the uPA ELISAs evoked the highest absorbance value com- 
pared with other standards, the same standard evoked only an 
intermediate signal in another uPA ELISA. It is plausible to 
assume that the differential specificity of the different sets of 
antibodies is involved in causing these discrepancies. For 
proper evaluation of the UPA content determined in tumour 
cytosols, applying different uPA ELISAs, it should be kept in 
mind that these kits contain standards which may differ in 
composition, use antibodies which often differ in specificity 
but quantify an analyte which is heterogeneous in nature. 
Thus, it is hardly surprising that the ranges in uPA levels, 
measured with different ELISAs, vary considerably. However, 
it is not possible retrospectively to relate the absolute UPA 
values reported in the literature with those obtained with 
different ELISAs. 
Taken together, this implies that multicentre studies with 
the goal of measuring uPA antigen in biological material in 
different laboratories should only be performed if the same 
type of uPA ELISA is used by all participating laboratories. In 
that case, the use of a stable reference material (tumour tissue 
extract) is very useful for normalisation of absolute values. In 
addition, such normalisation of values should result in lower 
interlaboratory CVs, but this will occur only if the intralabora- 
tory variation of the determination of uPA by ELISA is 
acceptably low. If such a reference sample is used throughout 
the study and the values reported assessed centrally, not only 
changes within any laboratory but also any changes between 
two batches of uPA ELISA will be quickly detected. There- 
fore, it is strongly recommended that a reference tumour 
tissue extract sample is applied in order to assure a high 
standard of quality control. From the present study, it appears 
that lyophilised breast cancer cytosols are stable over a long 
period of time and can thus serve as an ideal reference sample 
for the assessment of uPA antigen in breast cancer tissue 
extracts. 
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